Abstract 5106
Background
Obesity is a well-known risk factor for colorectal cancer (CRC), the relative risk being higher in men than in women, and for colon than for rectal cancer. Whether this risk differs by sidedness of colon cancer and sex, has however not yet been explored.
Methods
Among 28098 participants in the Malmö Diet and Cancer study, 11063 men and 17035 women, 584 incident CRC cases had been registered by Dec 31 2008. Seven anthropometric factors; height, weight, bodyfat%, hip circumference, waist circumference, BMI and waist-hip ratio (WHR) were categorized into quartiles (Q). Hazard ratios (HR) of CRC risk according to tumour location (right colon, left colon, rectum) and sex were calculated using multivariable Cox regression models, adjusted for age, smoking, educational level and alcohol intake.
Results
In men, several anthropometric factors were associated with an increased risk of right-sided colon cancer (HR for Q1[ref]-Q4 for weight 1.0, 1.67, 1.99, 2.88, ptrend= 0.001; waist circumference 1.0, 0.64, 1.59, 2.03, ptrend= 0.002; WHR 1.0, 0.73, 1.93, 1.89, ptrend= 0.004; BMI 1.0, 1.29, 1.50, 2.64, ptrend= 0.001), only WHR with left-sided colon cancer (1.0, 1.26, 1.94, 2.06, ptrend= 0.021), and none with rectal cancer. In women, body size was not associated with risk for neither right-sided nor left-sided colon cancer, only with rectal cancer (bodyfat% 1.0, 1.57, 2.18, 1.94, ptrend= 0.032, hip circumference 1.0, 1.76, 1.45, 2.18, ptrend= 0.033). Significant interactions with sex were denoted for hip circumference (p = 0.032) and BMI (p = 0.026) in relation to risk of right-sided colon cancer.
Conclusions
These data unveil a sexual dimorphism in the relationship between obesity and right-sided colon cancer, only being evident in men. As right-sided tumours are otherwise more common in women, hormonal factors may be particularly influential in their carcinogenesis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Lund University.
Funding
The Swedish Cancer Society, the Swedish Research Council, the Swedish Government Grant for Clinical Research, the Mrs Berta Kamprad Foundation, Lund University Faculty of Medicine and University Hospital Research Grants.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3536 - Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis
Presenter: Mylin Torres
Session: Poster Display session 2
Resources:
Abstract
4022 - Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial
Presenter: Mario Campone
Session: Poster Display session 2
Resources:
Abstract
3599 - Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices
Presenter: Rachel Layman
Session: Poster Display session 2
Resources:
Abstract
901 - Pharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumors
Presenter: Yung-Jue Bang
Session: Poster Display session 2
Resources:
Abstract
2777 - A Phase 2 study of abemaciclib in patients (pts) with brain metastases (BM) secondary to non-small cell lung cancer (NSCLC) or melanoma (MEL).
Presenter: Solmaz Sahebjam
Session: Poster Display session 2
Resources:
Abstract
3980 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
Presenter: Michelino De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
4024 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase 3b CompLEEment-1 trial
Presenter: Paul Cottu
Session: Poster Display session 2
Resources:
Abstract
2151 - Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract
3994 - Safety and efficacy of Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study.
Presenter: Michele De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
1370 - Interim Results From CompLEEment-1 (A Phase 3b Study of Ribociclib and Letrozole as First-Line Therapy for Advanced Breast Cancer in an Expanded Population): Spanish cohort results
Presenter: Javier Salvador
Session: Poster Display session 2
Resources:
Abstract